Sunday, December 21, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Ratings and Price Targets for Definitive Healthcare

Elaine Mendonca by Elaine Mendonca
March 1, 2024
in Breaking News
0
EEFT stock news
0
SHARES
5
VIEWS
Share on FacebookShare on Twitter

Analyst Ratings on Definitive Healthcare
_____________________________________________________________________________________

Analysts have been sharing their views on Definitive Healthcare (NASDAQ:DH) in recent months, with opinions ranging from bullish to bearish. Here’s a summary of the latest analyst ratings and price targets:

Ratings Overview:
Total Ratings: 1 Bullish, 0 Somewhat Bullish, 3 Indifferent, 0 Somewhat Bearish, 0 Bearish.
Last 30 Days: 0 Bullish, 0 Somewhat Bullish, 1 Indifferent, 0 Somewhat Bearish, 0 Bearish.
1 Month Ago: 0 Bullish, 0 Somewhat Bullish, 1 Indifferent, 0 Somewhat Bearish, 0 Bearish.

Price Targets:
Average Target: $10.5
High Estimate: $11.00
Low Estimate: $10.00
Current Average Target Increase: 1.65% from the previous average of $10.33.

Key Analyst Actions and Insights:
Saket Kalia from Barclays upgraded the rating to Equal-Weight with a price target of $11.00. David Hayes from Canaccord Genuity changed the rating to Hold with a price target of $10.00. Conversely, David Grossman from Stifel downgraded the rating to Buy with a price target of $11.00.

Key Insights:
Analysts make adjustments to their recommendations based on market conditions and company performance.
The consensus rating score for Definitive Healthcare is currently at 2.50.
Analysts predict a potential upside of approximately 17.98% based on their forecasts.

For more in-depth information on analyst coverage and ratings for Definitive Healthcare, please visit the Definitive Healthcare Corp Investor Relations page.

DH Stock Shows Positive Momentum on March 1, 2024: Investors Encouraged by Price Increase

On March 1, 2024, DH stock showed positive price momentum as it traded in the middle of its 52-week range and above its 200-day simple moving average. The price of DH shares increased by $0.32 since the market last closed, representing a 3.48% rise. The stock closed at $9.52, showing a positive movement in the price. Despite the drop in pre-market trading, the overall performance of DH stock on March 1, 2024, was positive. Investors may have been encouraged by the price momentum and the increase in the stock price since the market last closed. It is important for investors to keep an eye on the market trends and news related to DH stock to make informed decisions about their investments.

DH Stock Analysis: Revenue Up, Net Income Down – Can Growth be Sustained?

On March 1, 2024, DH stock had a mixed performance based on the financial data provided by CNN Money. The total revenue for the company was reported at $251.41 million for the past year, representing a 12.92% increase compared to the previous year. However, the total revenue remained flat at $65.93 million for the last quarter.

The net income for DH was reported at -$202.39 million for the past year, showing a significant decrease of 2702.38% compared to the previous year. On the other hand, the net income improved slightly to -$10.23 million for the last quarter, with a 0.0% increase compared to the previous quarter.

Earnings per share (EPS) for DH stock were reported at -$1.79 for the past year, reflecting a decrease of 2413.73% compared to the previous year. The EPS improved slightly to -$0.09 for the last quarter, with a 0.0% increase compared to the previous quarter.

Overall, DH stock had a challenging year in terms of financial performance, with a significant decrease in net income and earnings per share. However, the company managed to increase its total revenue compared to the previous year. The flat performance in the last quarter indicates that the company may be facing some challenges in maintaining its growth momentum.

Investors and analysts will be closely monitoring DH stock in the coming months to see if the company can improve its financial performance and drive growth in the future. It will be important for DH to address the issues that led to the significant decrease in net income and earnings per share in order to regain investor confidence and drive stock performance.

Tags: DH
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
FLO stock news

Analysts Evaluation and Price Targets for KimberlyClark Stock March 1 2024

Title Cullinan Oncology Receives FDA Approval for Groundbreaking Cancer Therapy with CLN619 Antibody

Finance_Financing

HC Wainwright Co Reiterates Buy Rating on Argenx ARGX with 451 Price Target

Recommended

JD.com Stock

Pivotal Week Ahead for JD.com as Major European Acquisition and EV Launch Converge

2 months ago
Snowflake Stock

Snowflake Faces Investor Confidence Test After Executive’s Rogue Forecast

2 months ago
Fiserv Stock

Fiserv’s Strategic Expansion Meets Legal Scrutiny

3 months ago
Does_Walmart_Take_Google_Pay

Does Walmart Take Google Pay? Exploring Walmart’s Exclusive Payment Solution

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin ASML BioNTech Bitcoin Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Intellia Therapeutics Faces Mounting Analyst Scrutiny Amid Regulatory Setback

Strategy Inc. Faces a Critical Index Classification Decision

DeFi Technologies Broadens Global Reach with New Listings and Products

Barrick Gold Secures Key Resolution in Mali, Paving Way for Mine Restart

Analyst Upgrade Sends Red Cat Shares Soaring

A Billion-Dollar Vote of Confidence for Standard Lithium

Trending

Tesla Stock
Automotive & E-Mobility

Tesla’s Valuation Faces Crucial Test Amid Legal Victory and Robotaxi Push

by Dieter Jaworski
December 21, 2025
0

Tesla shares are trading near their 52-week high as the company approaches a pivotal week, fueled by...

Wolfspeed Stock

Wolfspeed Secures Financial and Strategic Milestones

December 21, 2025
Textron Stock

Textron Stock Approaches Annual Peak Amid Strategic Wins

December 21, 2025
Intellia Therapeutics Stock

Intellia Therapeutics Faces Mounting Analyst Scrutiny Amid Regulatory Setback

December 21, 2025
Strategy Stock

Strategy Inc. Faces a Critical Index Classification Decision

December 21, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Tesla’s Valuation Faces Crucial Test Amid Legal Victory and Robotaxi Push
  • Wolfspeed Secures Financial and Strategic Milestones
  • Textron Stock Approaches Annual Peak Amid Strategic Wins

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com